Joseph joined IP Group in 2018, where he plays an active role within the life sciences team to identify and advance early-stage innovations into impactful companies.
Over his more than 25-year career in the biopharma, tech transfer and business development sectors, Joseph has worked with diverse groups of stakeholders to enable the translation of technologies to impact the lives of patients in need. Joseph has extensive experience in pre-clinical drug development at biopharma companies such as Wyeth, Millennium Pharmaceuticals, and Sirna Therapeutics. He also co-founded a successful RNAi-based venture, Skinetics Biosciences, Inc.
Joseph held various senior executive roles in the technology transfer sector at a number of prestigious institutions such as the University of Colorado, Dublin City University’s Biomedical Diagnostics Institute and OHSU’s Knight Cancer Institute. In his various roles in these institutions, Joseph worked to commercialize innovative technologies, facilitate greater academic-industry partnership and lead new venture creation.
Joseph earned a PhD in Cellular and Molecular Biology from the State University of New York (SUNY) at Stony Brook and a BS from Beloit College.